Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced that its management team will participate in a fireside chat and one-on-one meetings at Cantor's 2026 Global Healthcare Conference, scheduled for September 9-11, 2026, in New York. President and CEO Seth Lederman, M.D., will present on September 10 from 3:55 to 4:25 p.m. ET. A live webcast and replay will be available through the Investors section of the Tonix website.
This participation comes at a pivotal time for Tonix, which recently achieved a major milestone with the approval of TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg), the first new treatment for fibromyalgia in over 15 years. The company has shifted from a development-stage biotech to a fully integrated commercial-stage company, and its presence at a major healthcare conference signals its intent to engage with the investment community and showcase its growth trajectory.
The approval of TONMYA not only addresses a significant unmet medical need but also provides a commercial foundation for the company. Fibromyalgia affects millions of patients worldwide, and the introduction of a novel therapy could reshape the treatment landscape. Tonix is now focused on maximizing the science behind TONMYA, with ongoing Phase 2 clinical trials evaluating its potential in major depressive disorder and acute stress disorder. These indications represent substantial market opportunities and could expand the drug's utility beyond its initial approval.
Beyond TONMYA, Tonix's CNS portfolio includes TNX-2900, a Phase 2-ready candidate for Prader-Willi syndrome, a rare genetic disorder. The company is also advancing immunology programs, including TNX-4800, a monoclonal antibody for Lyme disease prophylaxis, and TNX-1500, a third-generation CD40 ligand inhibitor aimed at preventing kidney transplant rejection. These programs highlight the breadth of Tonix's research and its commitment to addressing high unmet needs in both CNS and immunology.
The company's participation in the Cantor conference provides a platform to discuss these developments with investors and analysts. The fireside chat with Dr. Lederman will likely cover the commercial launch of TONMYA, pipeline progress, and strategic priorities. One-on-one meetings offer an opportunity for deeper engagement with potential and current shareholders.
Tonix's journey from a development-stage company to a commercial entity is a testament to its scientific rigor and execution capabilities. The approval of TONMYA was a significant validation of its approach, and the company is now leveraging that success to build a sustainable business. The additional indications under investigation could significantly expand the patient population eligible for TONMYA, potentially driving long-term revenue growth.
Investors and industry observers will be watching closely as Tonix navigates this critical phase. The company's ability to successfully commercialize TONMYA while advancing its pipeline will be key to its future valuation. The Cantor conference provides a valuable opportunity for management to articulate its vision and update the market on recent progress.
For more information about Tonix Pharmaceuticals and its product candidates, visit the company's newsroom at https://nnw.fm/TNXP.
